The role of TNF-a promoter polymorphisms in the development of multiple myeloma ( MM ) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone ( Thal + Dex ) regimen .